nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-FC8AF2A0·Framework v5.13·Pipeline v0.4·Evaluated 22 Nov 2026·OECD: 3.2 Clinical medicine·Subfield: Pharmacology (medical)·Basis: Full text·Type: Randomized controlled trial

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial

2026·The Lancet·10.1016/s0140-6736(26)01861-1 ↗

Primary claim

In adults with obesity and type 2 diabetes, once-weekly retatrutide over 80 weeks produced weight reduction of up to 18·8% from baseline with an estimated treatment difference of -13·8% versus placebo

Well-supported · large randomised placebo comparison with precise estimates and multiplicity-controlled testing
In brief

Retatrutide delivers substantial 80-week weight and glycaemic benefits versus placebo in obesity with type 2 diabetes, but comparative superiority remains untested.

ReliabilityNo concerns4 of 4 checks completeRead the entry ↓
Likely to hold — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract not available — view at DOI ↗

Key Claims

Primary finding · Well-supported

In adults with obesity and type 2 diabetes, once-weekly retatrutide over 80 weeks produced weight reduction of up to 18·8% from baseline with an estimated treatment difference of -13·8% versus placebo

Likely to hold — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

large randomised placebo comparison with precise estimates and multiplicity-controlled testing

Conclusion; Results; Table 2
Quote verified
Secondary · Well-supported

The mean change from baseline in HbA1c at Week 80 was −1·38% (SE 0·06), −1·50% (0·07), and −1·45% (0·07) with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with −0·45% (0·08) for placebo.

prespecified glycaemic endpoint supported by precise randomised comparisons and multiplicity-controlled testing

Results, HbA1c; Table 2
Quote verified
Secondary · Well-supported

[Weight reduction reached] up to 21·9% in participants with baseline BMI ≥35 kg/m²

prespecified multiplicity-controlled subgroup estimate without implying a treatment-by-BMI interaction

Discussion; Results; Table 2
Quote verified
Secondary · Tentative

The safety profile was generally similar to other GLP-1 and GIP/GLP-1 receptor agonists, with the most commonly reported adverse events being gastrointestinal events with retatrutide treatment.

indirect comparisons without active controls and exploratory safety analyses limit conclusions about similarity

Research in Context; Table 3
Quote verified
Secondary · Tentative

Treatment with retatrutide resulted in significant body weight reductions beyond those previously observed in this population with GLP-1 and GIP/GLP-1 receptor agonists.

placebo-controlled design cannot identify comparative efficacy against active drugs across different trial populations

Research in Context, Added value of this study
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Precise evidence for sustained weight reduction

At 80 weeks, retatrutide 12 mg produced an estimated 18.8% weight reduction versus 5.1% with placebo, with a placebo-adjusted difference of −13.8 percentage points. HbA1c also improved across all retatrutide doses.

↳ Results; Table 2

#methodological rigour

Randomised design with explicit analytical safeguards

Central stratified randomisation and double masking are paired with randomised-population analyses, two prespecified estimands and multiplicity control for primary and key secondary endpoints.

↳ Methods, Randomisation and masking and Statistical analysis; Tables 1–2

#methodological rigour

Systematic collection and reporting of harms

Safety reporting includes discontinuations, deaths and prespecified events of interest, with independent adjudication of cardiovascular, pancreatic and neurological events. Gastrointestinal events, dysesthesia and hypotension are explicitly reported.

↳ Methods, Outcomes; Results, safety; Table 3

Limitations

#positioning

Active drug superiority remains an indirect inference

The placebo-controlled trial cannot establish superiority to other obesity medications despite wording about reductions beyond those previously observed. One contextual benchmark also relies on unpublished TRIUMPH-1 data.

↳ Research in Context, Added value; Discussion; References, item 13

#methodological rigour

Missing outcome assumptions remain clinically relevant

Treatment discontinuation ranged from 10% to 21% across arms. Multiple imputation addresses missing outcomes, but the main text does not state the proportion of Week-80 measurements observed rather than imputed.

↳ Methods, Statistical analysis; Results, participant disposition

#reporting

Broader benefit and safety claims need qualification

Quality-of-life language extends beyond the principal controlled physical-function comparison, while other risk-factor findings are not uniformly established across doses. Exploratory safety analyses do not settle rare or longer-term harms.

↳ Methods, Outcomes and Statistical analysis; Conclusion; Tables 2–3

Does this match your read? Add your assessment ↓

Nabu Commentary

The trial establishes substantial weight reduction and improved glycaemic control versus placebo over 80 weeks, with precise estimates in Table 2. Central randomisation, masking, explicit estimands and systematic harms collection support the methodological assessment. Differential discontinuation makes the missing-data assumptions relevant, even though the analyses use multiple imputation rather than a completers-only approach. Quantitative comparisons with contemporary trials provide context but cannot establish active-drug superiority, and the broader quality-of-life and safety language requires more qualification than the primary efficacy findings.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
4.2±0.1

Contribution
3.9

The trial provides precise 80-week placebo-controlled evidence for substantial weight reduction and improved HbA1c in adults with obesity and type 2 diabetes. It extends prior retatrutide evidence in duration and population, while comparative standing against other drugs remains indirect.

Introduction; Results; Table 2; Discussion
Methodological Rigour
4.4

Central stratified randomisation, masking, randomised-population analyses, prespecified estimands, multiplicity control and systematic harms assessment support the score. Differential treatment discontinuation and an unstated observed-versus-imputed Week-80 fraction leave uncertainty about missing-data assumptions.

Methods, Randomisation and masking, Outcomes and Statistical analysis; Results, participant disposition; Tables 1–3
Reporting
4.1

The manuscript clearly separates estimands and reports absolute changes alongside placebo differences. Cross-trial comparative wording and broad quality-of-life language are less precise than the otherwise explicit endpoint reporting.

Research in Context, Added value; Methods, Statistical analysis; Conclusion; Table 2
Positioning
3.9

The Discussion quantitatively engages contemporary incretin trials and acknowledges absent active comparisons, unmeasured body composition and uncertain durability. Reliance on an unpublished benchmark and incomplete discussion of population restrictions limit the contextual interpretation.

Methods, Study design and participants; Discussion; References, item 13

Lower confidence on Methodological Rigour, Positioning — domain match limited.

Reliability

No concerns4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyClean

Ethics approval, consent, registration, sponsor involvement and conflicts of interest are declared, with conditional participant-data access described. External verification of the unpublished comparator study is an assessability gap rather than a conduct finding.

Conflict of interest: declared · Ethics approval: declared · Preregistration: declared · Data availability: declared

Reference IntegrityNoted

18 of 21 checkable references verified

22 references in manuscript 1 are books, websites or datasets — counted, but not index-checkable

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 22 Nov 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Metabolic and endocrine · Diabetes mellitus
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim is tested in a completed phase 3 randomised placebo-controlled trial of 1152 participants across 92 sites in 8 countries, which is a large confirmatory multicentre setting.

From the paper
“These results show that retatrutide may be effective for the treatment of obesity in people with type 2 diabetes.”

The paper names a real-world use of its own findings, treating obesity in people with type 2 diabetes, but does not say which professionals or services would act on them.

Pathway

If regulators approve retatrutide, endocrinologists and obesity clinicians could prescribe it to achieve weight reduction in patients with obesity and type 2 diabetes.

Barrier

The drug needs regulatory approval and lacks data on long-term weight maintenance, hard cardiometabolic outcomes, and comparison against active obesity treatments.

Evaluated 22 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Pain as an assault on the self: An interpretative phenomenological analysis of the psychological impact of chronic benign low back pain

    Jonathan Ashley Smith, Mike Osborn · 2006 · Psychology and cognitive sciences

    Primary claim

    The notion of the self emerged in this study as an important aspect of the participants’ experience of chronic pain sensation, distress and disability.

    Supported
    Evidence Score
    3.5±0.1
    Reliability
    No concerns
  2. Definition of treatment-resistant late-life depression: Conclusions from a European Task Force Delphi process

    Pozuelo Moyano, von Gunten, Mueller, et al. · 2026 · Clinical medicine

    Primary claim

    Experts agreed that the categorical definition of TRLLD should correspond to major depressive disorder in individuals aged ≥65 years who show insufficient response to two adequate antidepressant treatments, in the absence of dementia and medical conditions that could account for depressive symptoms.

    Supported
    Evidence Score
    3.7±0.2
    Reliability
    Caveats
  3. Deficits in episodic memory and executive functions in relation to CB1 receptor availability in Parkinson's disease

    Ajalin, Al-Abdulrasul, Tuisku, et al. · 2026 · Neurology and psychiatry

    Primary claim

    Decreased CB1R availability in PD patients is correlated with episodic memory impairment and executive dysfunction, suggesting that the ECS has a role in the pathophysiology of cognitive symptoms in PD.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    Caveats

How the rubric works →